Moderna asks FDA to authorize first COVID-19 vaccine for very young children
The company says a low-dose version of its vaccine triggers an immune response in children ages 6 months to less than 6 years equivalent to what has protected older children and adults.
Moderna announced Thursday that the company has asked the Food and Drug Administration to authorize a low-dose version of its COVID-19 vaccine as the first vaccine for children younger than age 5.
In a study involving about 6,700 children, the company said two-doses of the vaccine administered 28 days apart to children ages 6 months to less than
